Study: Acomplia Increases the Likelihood of Success in Quitting Smoking
Researchers at the University of Cincinnati Acomplia (rimonabant) College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared with placebo, markedly reduced post-cessation weight gain at 10 weeks, and was well-tolerated Acomplia (rimonabant) .
“ Smoking cessation Acomplia (rimonabant) is an enormous struggle for many people,” said Robert Anthenelli, M.D., one of the principal investigators in the STRATUS US trial and an associate professor of Psychiatry at the University of Cincinnati College of Medicine and Cincinnati VA Medical Center. “People who smoke are at high risk for cardiovascular disease. It is imperative to do anything and everything we can to treat tobacco dependence. Rimonabant represents a potentially promising new treatment option that can help people stop smoking while curbing post cessation weight gain. This may be a major step forward in smoking cessation Acomplia (rimonabant) . ”
Rimonabant is the first in a new class of drugs called Selective CB1 Blockers. The drug works by inhibiting the CB1 receptor, one of two receptors found in the EndoCannabinoid System (or EC System), that are located in the brain and in other parts of the body. Associated with systems regulating the body’s intake of food, the EC system is also involved in tobacco dependency. Chronic tobacco use over-stimulates the EC system creating an imbalance Acomplia (rimonabant) .
By blocking the CB1 receptor, rimonabant helps restore balance to the EC system resulting in reduced dependence on tobacco. In addition, in other clinical trials with rimonabant, researchers discovered that CB1 receptors are also found in adipose tissue ((fat cells), Acomplia (rimonabant) which are associated with lipid and glucose metabolism.
Blocking CB1 receptors in this part of the body has shown, in a recently completed obesity clinical trial called RIO-LIPIDS, results of which were also presented at the American College of Cardiology, that rimonabant not only significantly induces significant weight loss but reduces abdominal fat in overweight//obese people with untreated dyslipidemia, and also increases HDL-cholesterol (good cholesterol), Acomplia (rimonabant) lowers triglycerides, and significantly improves impaired glucose and insulin levels, all contributing risk factors for cardiovascular disease.
“ It is widely known Acomplia (rimonabant) that smoking is linked to respiratory diseases and lung cancer, but smokers are also at 70% greater risk for cardiovascular disease than non smokers,” said Dr. Anthenelli.
“ Since these two studies Acomplia (rimonabant) show that rimonabant treats obesity and related metabolic disorders in overweight//obese patients, and also helps people to quit smoking without significant post-cessation weight gain, we may have a very promising new approach for Acomplia (rimonabant) managing two major and preventable risk factors for cardiovascular disease with one and the same drug.”
Метки:clinical, drug, fat, loss, medicine, obese, obesity, results, smoking, study, weight, Zimulti
Посмотрите также
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.